Mega MS - Search Results

1

Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease.

Mega MS, Cummings JL, O'Connor SM, Dinov ID, Reback E, Felix J, Masterman DL, Phelps ME, Small GW, Toga AW. Mega MS, et al. Neuropsychiatry Neuropsychol Behav Neurol. 2001 Jan;14(1):63-8. Neuropsychiatry Neuropsychol Behav Neurol. 2001. PMID: 11234910 Clinical Trial.

2

The spectrum of behavioral changes in Alzheimer's disease.

Mega MS, Cummings JL, Fiorello T, Gornbein J. Mega MS, et al. Neurology. 1996 Jan;46(1):130-5. doi: 10.1212/wnl.46.1.130. Neurology. 1996. PMID: 8559361

3

Mapping histology to metabolism: coregistration of stained whole-brain sections to premortem PET in Alzheimer's disease.

Mega MS, Chen SS, Thompson PM, Woods RP, Karaca TJ, Tiwari A, Vinters HV, Small GW, Toga AW. Mega MS, et al. Neuroimage. 1997 Feb;5(2):147-53. doi: 10.1006/nimg.1996.0255. Neuroimage. 1997. PMID: 9345544

4

Sulcal variability in the Alzheimer's brain: correlations with cognition.

Mega MS, Thompson PM, Cummings JL, Back CL, Xu ML, Zohoori S, Goldkorn A, Moussai J, Fairbanks L, Small GW, Toga AW. Mega MS, et al. Neurology. 1998 Jan;50(1):145-51. doi: 10.1212/wnl.50.1.145. Neurology. 1998. PMID: 9443471

5

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease.

Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL. Mega MS, et al. Arch Neurol. 1999 Nov;56(11):1388-93. doi: 10.1001/archneur.56.11.1388. Arch Neurol. 1999. PMID: 10555660

6

Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease.

Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME. Small GW, et al. Among authors: mega ms. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6037-42. doi: 10.1073/pnas.090106797. Proc Natl Acad Sci U S A. 2000. PMID: 10811879 Free PMC article.

7

Cerebral correlates of psychotic symptoms in Alzheimer's disease.

Mega MS, Lee L, Dinov ID, Mishkin F, Toga AW, Cummings JL. Mega MS, et al. J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):167-71. doi: 10.1136/jnnp.69.2.167. J Neurol Neurosurg Psychiatry. 2000. PMID: 10896687 Free PMC article. Clinical Trial.

8

Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease.

Mega MS, Dinov ID, Lee L, O'Connor SM, Masterman DM, Wilen B, Mishkin F, Toga AW, Cummings JL. Mega MS, et al. J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):209-18. doi: 10.1176/jnp.12.2.209. J Neuropsychiatry Clin Neurosci. 2000. PMID: 11001599 Clinical Trial.

9

Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction.

Senanarong V, Cummings JL, Fairbanks L, Mega M, Masterman DM, O'Connor SM, Strickland TL. Senanarong V, et al. Dement Geriatr Cogn Disord. 2004;17(1-2):14-20. doi: 10.1159/000074080. Epub 2003 Oct 13. Dement Geriatr Cogn Disord. 2004. PMID: 14560060

10

Quantitative comparison and analysis of brain image registration using frequency-adaptive wavelet shrinkage.

Dinov ID, Mega MS, Thompson PM, Woods RP, Sumners DL, Sowell EL, Toga AW. Dinov ID, et al. Among authors: mega ms. IEEE Trans Inf Technol Biomed. 2002 Mar;6(1):73-85. doi: 10.1109/4233.992165. IEEE Trans Inf Technol Biomed. 2002. PMID: 11936599

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

47 results

Search Page

Filters